MarketCap
Facebook
X
TelegramAnnual report 2023
added 02-22-2024
Karuna Therapeutics Total Liabilities 2011-2026 | KRTX
Annual Total Liabilities Karuna Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82 M | 37.1 M | 25.6 M | 8.69 M | 3.11 M | 909 K | 15.5 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 82 M | 909 K | 24.7 M |
Quarterly Total Liabilities Karuna Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62.8 M | 52.5 M | 28 M | 37.1 M | 44.5 M | 28.1 M | 20.8 M | 25.6 M | 21.8 M | 16.8 M | 8.35 M | 8.69 M | 8.69 M | 8.69 M | 8.69 M | 3.11 M | 3.11 M | 3.11 M | 3.11 M | 3.81 M | 3.81 M | 3.81 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 62.8 M | 3.11 M | 18.4 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M |  USA |
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Adaptimmune Therapeutics plc
ADAP
|
243 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Aptorum Group Limited
APM
|
4.35 M | $ 0.83 | 2.17 % | $ 4.53 M |  China |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M |  Canada |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M | China |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
BioNTech SE
BNTX
|
3.12 B | $ 110.14 | 3.3 % | $ 27.2 B | Germany |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
38.7 M | $ 2.6 | -1.12 % | $ 146 M | China |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.51 | -0.52 % | $ 8.45 B |  Australia |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 4.21 | 1.2 % | $ 9.16 B |  Israel |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
90.7 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
272 M | $ 1.49 | 7.19 % | $ 279 M | USA |
 |
Aptose Biosciences
APTO
|
14.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
1.29 B | $ 221.8 | -0.16 % | $ 5 B |  Danmark |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
110 M | - | -6.81 % | $ 3.04 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
38.9 M | - | 17.91 % | $ 11.1 M | USA |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 8.96 | 0.45 % | $ 1.41 B | Britain |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Athira Pharma
ATHA
|
13.9 M | - | - | $ 269 M | USA |
 |
Athersys
ATHX
|
28.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
355 M | $ 1.46 | 2.46 % | $ 373 M | Britain |
 |
Amneal Pharmaceuticals
AMRX
|
3.32 B | $ 14.49 | -0.24 % | $ 4.48 B | USA |
 |
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.35 | -1.81 % | $ 14.8 M | USA |
 |
AstraZeneca PLC
AZN
|
63.2 B | - | - | $ 96.9 B | Britain |
 |
Brickell Biotech
BBI
|
6.5 M | - | -5.38 % | $ 6.06 M | USA |